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In the TAMI 5 Trial 575 patients with acute myocardja~ infarction 
were randomized in a factorial design to treatment with a fibrin- 
specific agent (t-PA-100 mg/3hrs), a nonspecific lytic agent 
urokinase (UK 3x108units/90mino) or the combination (COMBO-t- 
PA Img/kg+WK ).5xlOeunits/Shr) and acute or pre-discharge car- 
diac catheterization. Prospectively, standard criteria for transfu- 
sion were set for the trial at hematocrit ( ) &2 or <25 with 
hemodynamic instability. Bleeding camp tions dur the entire 
hospita! course were measured in terms of units of packed red 
blood cells transfused and change in hematocrit from admission to 
nadir ( XT). in preliminary analysis of the 453 patients treated 
without coronary bypass surgery* HCT did not vary by drug 
regimen (UKzg.9; t-PA:9.4; COMBO:g.6) or cath strategy (Acute 9.3; 
Predischarge 8.5). Nadir Hct by drug regimen was U 
BtI35 and by cath strategy was Acnte:34, Predis 
Similarly, no substantial differences were found in t~nsf~sion 
rates (22 units) by drug strategy (WK:tO%, t-PA:9%, C0MB01:12%) or 
by cath strategy (Acute:! 1%. Predischarge:lIO%). When surgical 
patients were also included, the overah bleeding rates were higher, 
but no differences among strategies were observed. The only 
catastrophic bleeding complications were irtra-cranial hemorrhages 
(t-PA:4, UIC2, COMBO:O); all pts died as a result. Thus, fibrin 
specificity does not confer an advantage with regard to bleeding 
r&k and judicious transfusion allows early catheterization to 
complished with minimal additional use of blood products. 
be ac- 
TQ ~~n~ua~e the outcome of double and triple vessel 
selected pts. 
